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Clinical trials conducted in developing
countries differ in many respects to those
carried out in the West; for example, they
are usually conducted in vulnerable pop-
ulations, focus mainly on infectious diseas-
es, and often have severe endpoints. In
these regions, trial capacity lags behind
that of wealthier nations, particularly in
terms of the ability of research sites to lead
broad and independent clinical research
programmes. Product development trials
are important for the registration of new
treatments and vaccines, yet do not leave
sites with the skills to run their own trials,
as protocol design, operational planning,
and data management are typically con-
ducted remotely by the sponsor. There is
also a need for more disease management
trials to examine and then improve health
outcomes, but the capacity to design and
execute such studies is often absent. The
process of increasing clinical trial capacity
should be led by the research sites and
tailored to their needs, as trial methods
and guidelines need to be appropriately
designed and crafted to be fit for purpose
in the developing country context. We
discuss the need to address the deficit in
capacity and training and propose a
collaborative solution for identifying the
gaps and then designing methods, guid-
ance, and sharing approaches to make
clinical trials less daunting and cumber-
some, particularly when being planned for
resource-limited settings.
Trials in Resource-Limited
Settings
Clinical trials establish the evidence
base for the prevention and treatment of
disease. They are critically important in
developing countries, not simply because
this is where the potential is greatest for
improving health in numerical terms (as
these regions have the highest diseases
burden), but also because there is enor-
mous potential gain from effective new
interventions and because these popula-
tions have been under-represented in
clinical research to date. The human and
material resource capacity available to
ensure a high standard of design, man-
agement, and operation of clinical trials in
developing countries lags far behind that
available in wealthier nations.
Although many of the issues con-
fronting clinical trialists working in re-
source-limited settings are the same as
those affecting academic researchers in the
wealthier regions of the world, there are
significant differences which both highlight
the issues involved and require specific
attention. In contrast to clinical trials in
wealthy countries, those in developing
countries frequently have endpoints that
are severe disease outcomes or mortality.
They more often involve children, focus
predominantly on infectious diseases, and
are more often sponsored by not-for-
profit organisations. We illustrate this
difference by taking a random sample of
100 trials registered at ClinicalTrials.gov
for each of the top five countries in Europe
and Africa and then classifying them
(Figure 1). Public health problems that
are specific to developing countries also
urgently require more and better clinical
trials to inform policy, such as the
management of disease outbreaks (includ-
ing those with pandemic potential) in
displaced populations, in refugee camps,
and following natural disasters. These very
specialised situations and environments
need new, highly practical, and appropri-
ate interpretation of regulations and
guidelines to enable rapid and flexible
trial implementation.
All Those Guidelines and
Regulations
Over recent years there has been
massive proliferation of regulations affect-
ing the conduct of clinical trials. This
process began in 1964 with the Declara-
tion of Helsinki made by the World
Medical Association (WMA) in response
to a tightening of legislation following the
thalidomide disaster in the 1960s [1,2].
The implementation of the declaration
resulted in the US Food and Drug
Administration (FDA) having to reject trial
data from countries with ethical and safety
standards that differed from the US. The
perceived differences between standards
drove the harmonisation process led by
regulators from Japan, Europe, and the
US, and experts from the pharmaceutical
industry, who produced, in 1996, the
International Conference on Harmonisa-
tion of Technical Requirements for Reg-
istration of Pharmaceuticals for Human
Use - Good Clinical Practice (ICH-GCP)
guidelines [3].
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International Organizations of Medical
Sciences (CIOMS) produced its Internation-
al Ethical Guidelines for Biomedical Research
Involving Human Subjects in 1982 [4].
Revised in 2002, these guidelines are
intended to guide lower-income countries
in applying the ethical principles that were
laid out in the Declaration of Helsinki.
Another set of international clinical trial
guidelines was produced by the World
Health Organization in 1995 [5]. The
WHO Guidelines for good clinical practice
(GCP) for trials on pharmaceutical products
were developed to provide a global
standard for clinical trials. They were
intended to complement existing regula-
tions in those WHO member states that
had already enforced clinical trials legisla-
tion or to provide a basis for new
regulations in countries that had not.
However, neither the CIOMS nor the
WHO guidelines hold the force of law,
and ICH-GCP is now the de facto global
standard by which trials are run and has
become a legal requirement for clinical
trial conduct in many countries. Consis-
tent criticisms of ICH-GCP are that it is
outdated, that not enough countries were
involved in its development, and that it is
focussed on the needs of industry and drug
registration with minimal representation
from academia and noncommercial orga-
nisations [6,7,8,9]. It is also focussed on
drugs as the intervention and so is difficult
to apply to other trials and broader types
of clinical research that would benefit from
sensible and appropriate quality and
ethical guidance.
The Declaration of Helsinki can also be
difficult to apply. For example, the posi-
tion of the WMA to insist that a medical
doctor be responsible for taking informed
consent is not practical or always appro-
priate. In our research sites, community-
based trials are very important to assess
proposed improved or new interventions.
Here, where there are rarely doctors
present, it would be inappropriate to
introduce a doctor where normally there
are nurses or clinical officers just for the
purposes of the trial. In these situations it
could be argued that the profession
responsible for administration of the
intervention is much better placed to
request fully informed consent from po-
tential participants.
In the US and Europe, as the regula-
tions and guidelines have become more
strongly enforced and embedded in legis-
lation, it has been increasingly recognised
that a high level of support is necessary to
help researchers run their trials. Recently
a network has been set up in the UK
specifically to support clinical trials in
children. The Medicines for Children
Research Network [10] is funded by the
UK’s Department of Health and recog-
nises that conducting trials in children has
very specific challenges and needs dedi-
cated experts to provide tools and guid-
ance. After the European Union made
ICH-GCP a legal requirement in 2004,
the UK’s Medical Research Council
(MRC) launched a Web site to help
noncommercial trialists find their way
through the guidelines and direct them
in what they need to ensure that their trials
are legal and compliant [11]. Since 2004,
most UK universities now have clinical
trials offices that support their academics
in conducting clinical trials. Universities
have made these provisions because as
sponsors they bear the legal burden of
ensuring that trials do not breach
ICH-GCP.
In the US, the FDA has partnered with
Duke University to establish the Clinical
Trial Transformation Initiative [12].
Their aim is to generate evidence on the
conduct of clinical trials that will improve
their quality and efficiency. This is a US-
focussed exercise that will examine current
practice under FDA requirements and
make recommendations to improve trial
conduct in the US so it is more straight-
forward and attractive to researchers.
These various initiatives set out to
unravel the guidelines and facilitate trial
conduct for non-commercial researchers
in their distinct environments. The same is
needed for the unique setting of develop-
ing country-based trials. However, any
such initiative should be led from the
perspective of these regions and by the
researchers working there. It should be
highly collaborative and must reflect the
real issues and gaps, which will need to be
continuously captured and monitored. In
addition, it must be broad enough to
provide support for all areas of trial
conduct, from governance and insurance
issues through to trial design and opera-
tions, and also have a strong focus on
training and career development. Any
guidelines or recommendations put for-
ward must be derived through a partici-
Figure1.Trials differ in Europe andAfrica. Classificationofa randomsample of100 trialsfor each offivecountriesinEurope(France,Germany,Italy,
Spain, and the United Kingdom) and Sub-Saharan Africa (Kenya, Mali, Tanzania, Uganda, and Zambia). Trials in Africa focus predominantly on paediatric
populations (A) and infectious disease (B) and are non-industry sponsored (C). Data were abstracted from the ClinicalTrials.gov website in August 2009.
doi:10.1371/journal.pntd.0000619.g001
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that they address the gaps and are
appropriate and practicable for this chal-
lenging environment.
Trials in Resource Limited
Settings, the Current Situation
The majority of clinical trials conducted
in developing countries have sponsors who
are based in Europe or the US. Trial
sponsors frequently demand that research
sites implement the sponsor’s own inter-
pretation of ICH-GCP, which is often over
and above what is actually required. This
is understandable as ICH-GCP is gener-
ally seen as the ‘gold standard’ for all
clinical research and the investigational
product research is typically aimed at US
FDA or European Medicines Agency
(EMA) licensure [9,13]. However, these
exacting standards and the associated
burden of process and paperwork can be
daunting for academic researchers and are
frequently inappropriate where they work
[8]. A more locally appropriate interpre-
tation of GCP guidelines is often possible
and provides just as high a standard in
terms of ethics and quality, but investiga-
tors either lack the confidence to develop
and propose pragmatic alternatives or are
not aware that they can and should.
As well as product development studies
there is also a need for more disease
management trials. These are often large
yet straightforward trials that assess wheth-
er new approaches could be made in
current treatment or care practices to
improve outcomes. Typically these trials
assess known drugs that have been widely
used in other settings. These studies can
make a significant impact on public health
practice. Examples of potential trial topics
include managing malnutrition or pre-
scribing antibiotics during childbirth. New
or adapted interventions can potentially
bring about dramatic reductions in mor-
tality, but they must be supported by
sound medical evidence, and researchers
need access to tools and training in order
to undertake trials to obtain this evidence.
Disease management studies such as these
that assess new uses for existing or licensed
practices or treatments are normally
associated with lower risk than trials that
evaluate new treatments. While the basic
principles of GCP are straightforward and
their application is important to ensure
high standards in ethics and data quality,
little guidance exists on how they should
be interpreted and applied in disease
management or other non-investigational
new product trials. It is important to
remember that these are guidelines, intend-
ed to be subject to varying interpretation
and application. Within ICH-GCP itself it
is repeatedly stated that the guidelines
should be interpreted and applied in a
manner appropriate to the risk of the
research. Pragmatic interpretation is need-
ed, because many aspects of ICH-GCP are
not applicable in disease management
trials and can be problematic when
applied to investigational new product
trials, especially in the specific situations
found in resource-limited settings. Addi-
tionally, there are fundamental areas, such
as randomisation, that ICH-GCP does not
cover. Robust randomisation of subjects
into groups is critical to rigorous trial
design, and its reliable implementation is
fundamental to producing a valid data-
set—i.e., the trial giving the right answer!
Straightforward guidance is required to
ensure that this can been done securely
and accurately.
The Need for a Research-Led,
Developing Country–Specific
Clinical Trial Programme
A major criticism of ICH-GCP is that it
was developed through a process of
informal consensus rather than through
research or evidence of best practices [6].
While programmes like the Duke-FDA
Clinical Trials Transformation Initiative
are seeking to gather evidence to improve
trial conduct in the US, no such initiatives
exist to support a broad range of trials in
the developing world.
A collaborative programme that is
designed specifically to support developing
country-based trials and is not disease
specific could benefit researchers in devel-
oping countries. It would work best if
participation were free and available on-
line. Such a collaboration could encourage
disease management research and product
development trials, and could give re-
searchers access to all they need from
training right through to template docu-
ments, suggested operating procedures,
and guidelines, all accessed from one site.
An important element of such a resource is
that it could offer advice, tools, and
guidance appropriately adjusted for all
types of trials with varying levels of risk. As
it would be specifically for researchers
working in these settings, it would be able
to focus on relevant issues such as
community participation in trials, which
is of particular importance when trials are
being conducted in vulnerable popula-
tions. Ultimately it could provide sensible
and pragmatic interpretations of good
clinical practice guidelines derived using
an evidence-based approach and make the
conduct of high-quality trial conduct
easier, less cumbersome, and much less
daunting. Such a site would benefit from
being highly interactive and allow re-
searchers to share their tools, experiences
and interpretations of the guidelines.
It is important to emphasise that the
need to facilitate trial conduct in resource-
limited settings does not mean developing
an approach that is in any sense substan-
dard or inferior. Developing country trials
require at least the same degree of
attention to the quality of processes and
procedures and of data management as
that required in resource-rich settings—
and the attention to international ethical
standards may need to be even greater
where vulnerable populations are in-
volved. A focussed effort is needed to
establish a straightforward system by
which researchers can navigate the regu-
lations and guidelines and determine what
is needed for their planned research and
appropriate for the context in which it will
be carried out.
Training and Professional
Development
In Europe and the US being a Clinical
Trials Scientist or ’’trialist’’ is a well
recognised profession. There are well
established and recognised professional
bodies [14,15], and numerous vocational
and academic qualifications are available
from diplomas through to doctorates, all
specific to the science and profession of
designing and conducting clinical trials.
Clinical trialists of all disciplines can be
found in universities, health organisations,
medical research charities, and industry.
In the regions where we work there is
limited recognition of the clinical trialist as
a profession or viable career path. We
believe this is a key factor impeding
capacity development. Many still see the
running of trials as an administrative
function. Taking a clinical question and
then developing a protocol and conduct-
ing a clinical trial to answer that question
is a research discipline that requires
training, experience, and critical thinking.
Only when there is a critical mass of
skilled trial coordinators, laboratory tech-
nicians, data managers, statisticians, mon-
itors, research nurses, and investigators
will research sites be in a position to design
and lead their own programmes.
Clinical trial staff in these regions would
benefit from a free online continuing
professional development scheme that
allows them to register their role, experi-
ence, training, and core competencies, and
then build points to track their competen-
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be linked to e-learning opportunities and
to a local network of shared real-life
training opportunities and mentoring.
Summary
Our aim is to raise awareness of the
issues faced by researchers in developing
countries and to introduce an initiative we
are developing.
We propose that the gaps and issues we
have outlined could be largely addressed
by building a community of researchers
from all the various roles who will be able
to access the information, guidance and
resources they need, whilst also be able to
share methods and pragmatic operational
practices that have been locally derived
and known to work. Some examples
include template consent forms, data
management systems, and example proto-
cols and laboratory sample collection and
handling methods.
We emphasize that this initiative is
entirely based on an ethos of collabora-
tion, open access, and sharing practice;
indeed it will only be successful if research
groups both use the resource and contrib-
ute to its development. The development
of a prototype of web site for this initiative
is underway and can be found at http://
pilot.globalhealthtrials.org/. We are mak-
ing this public at this early juncture as we
are seeking involvement from our col-
leagues right from the outset in line with
the open and collaborative ethos that is
envisaged. Therefore, we encourage col-
leagues to become part of this initiative by
providing content, commenting on the
Web site, and sharing their operational
tools. We also welcome all those engaged
in trials to register and build their own
personal professional development record
to track their career and training record,
and to provide a review structure.
Conclusion
To improve clinical trial conduct in
resource-limited settings we need easier
operational tools and guidance as well as
skilled staff. This needs to be more than
conducting externally sponsored trials that
are designed and led elsewhere. We
suggest true capacity-building might be
best achieved by establishing a community
of developing country based researchers to
share locally derived solutions and build a
set of validated methods and operational
tools that will enable pragmatic and locally
led development.
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